Cerus Corporation reported second quarter 2026 financial results with total revenue of $63.3 million, a 5% increase year-over-year, driven by a 10% rise in product revenue to $57.4 million. The company raised its full-year 2026 product revenue guidance to $229–$231 million and increased its IFC sales outlook to $23–$25 million. Cerus completed a debt refinancing, reducing the term loan by $30 million using cash on hand and new borrowings under a lower-cost facility. Additionally, the company expanded its BARDA collaboration, increasing the contract's total potential value by $21.9 million to $270.5 million. Cerus Corporation develops pathogen reduction technologies and blood safety products for hospitals and blood centers.

William "Obi" Greenman transitioned from President and Chief Executive Officer to Executive Chairman of the Board effective July 1, 2026. Under the amended employment agreement, he will receive an annual base salary of $500,000 and a 2026 target cash bonus opportunity of 80% of his base salary. Cerus Corporation is a biotechnology company that develops and manufactures blood safety technologies.

Cerus Corporation entered into amended and restated credit, security and guaranty agreements, including a $65.0 million term loan facility and a $30.0 million revolving credit facility. The company borrowed $35.0 million in the first tranche of the term loan to refinance existing debt, and $29.9 million was outstanding under the revolving credit facility at closing.